A prospective, longitudinal study of sleep disturbance and comorbidity in opiate dependence (the ANRS Methaville study)
Rationale/objectives Sleep disturbance is frequent in opioid-dependent patients. To date, no data are available about the impact of methadone maintenance treatment on sleep disturbance. Using 1-year follow-up data from the Methaville trial, we investigated the impact of methadone initiation and othe...
Gespeichert in:
| Veröffentlicht in: | Psychopharmacology 2016-04, Vol.233 (7), p.1203-1213 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1213 |
|---|---|
| container_issue | 7 |
| container_start_page | 1203 |
| container_title | Psychopharmacology |
| container_volume | 233 |
| creator | Nordmann, Sandra Lions, Caroline Vilotitch, Antoine Michel, Laurent Mora, Marion Spire, Bruno Maradan, Gwenaelle Morel, Alain Roux, Perrine Carrieri, M. Patrizia |
| description | Rationale/objectives
Sleep disturbance is frequent in opioid-dependent patients. To date, no data are available about the impact of methadone maintenance treatment on sleep disturbance. Using 1-year follow-up data from the Methaville trial, we investigated the impact of methadone initiation and other correlates on sleep disturbance in opioid-dependent patients.
Methods
Sleep disturbance severity was evaluated using two items from different scales (Center for Epidemiological Studies Depression Scale for depression and Opiate Treatment Index). We assessed the effect of methadone and other correlates on sleep disturbance severity during follow-up (months 0, 6, and 12) using a mixed multinomial logistic regression model.
Results
We included 173 patients who had 1-year follow-up data on sleep disturbance, corresponding to 445 visits. At enrolment, 60.5 % reported medium to severe sleep disturbance. This proportion remained stable during methadone treatment: 54.0 % at month 6 and 55.4 % at month 12. The final multivariate model indicated that younger patients (odds ratio (OR) [95 % CI] 0.95 [0.90–1.00]), patients with pain (OR [95 % CI] 2.45 [1.13–5.32]), patients with high or very high nicotine dependence (OR [95 % CI] 5.89 [2.41–14.39]), and patients at suicidal risk (2.50 [1.13–5.52]) had a higher risk of severe sleep disturbance. Because of collinearity between suicidal risk and attention deficit hyperactivity disorder (ADHD) symptoms, ADHD was not associated with sleep disturbance in the final model. Receiving methadone treatment had no significant effect on sleep disturbance.
Conclusions
Sleep disturbance is frequent among opioid-dependent patients. It can be regarded as an important signal of more complex psychiatric comorbidities such as suicidal risk and ADHD. However, sleep disturbance should not be considered an obstacle to methadone maintenance treatment (MMT) initiation or continuation. |
| doi_str_mv | 10.1007/s00213-016-4202-4 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1780531585</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A447064533</galeid><sourcerecordid>A447064533</sourcerecordid><originalsourceid>FETCH-LOGICAL-c472t-29f74b7fa97c1d55d881c507aef3a34e63635e1287f282ccb0a9dafaca1f98713</originalsourceid><addsrcrecordid>eNqNkstu1TAQhi0EoqeFB2CDLLEpEim-xsnyqIKCVEDisrYce3zqKscOcVJ03h6HlKtAwl7YGn__aGb8I_SIkjNKiHqeCWGUV4TWlWCEVeIO2lDBWcWIYnfRhhDOK05lc4SOc74mZYlG3EdHrFaSq5Zt0JctHsaUB7BTuIFnuE9xF6bZhWh6nMvlgJPHuQcYsAslMHYmWsAmOmzTPo1dcGE64BBxGoKZADsYIDpYoNPpCvD27fsP-A1MV-Ym9D2sSZ8-QPe86TM8vD1P0KeXLz6ev6ou3128Pt9eVlYoNlWs9Up0yptWWeqkdE1DrSTKgOeGC6h5zSVQ1ijPGmZtR0zrjDfWUN82ivITdLrmLV1-niFPeh-yhb43EdKcNVUNkcuI5H-gy9AK2Bb0yR_odZrHMrJvVKm8lar5Se1MDzpEn6bR2CWp3gqhSC0k54U6-wtVtoN9sCmCDyX-m4CuAls-Lo_g9TCGvRkPmhK9-EKvvtDFF3rxhRZF8_i24Lnbg_uh-G6EArAVyOUp7mD8paN_Zv0KyvPBBA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1774729578</pqid></control><display><type>article</type><title>A prospective, longitudinal study of sleep disturbance and comorbidity in opiate dependence (the ANRS Methaville study)</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Nordmann, Sandra ; Lions, Caroline ; Vilotitch, Antoine ; Michel, Laurent ; Mora, Marion ; Spire, Bruno ; Maradan, Gwenaelle ; Morel, Alain ; Roux, Perrine ; Carrieri, M. Patrizia</creator><creatorcontrib>Nordmann, Sandra ; Lions, Caroline ; Vilotitch, Antoine ; Michel, Laurent ; Mora, Marion ; Spire, Bruno ; Maradan, Gwenaelle ; Morel, Alain ; Roux, Perrine ; Carrieri, M. Patrizia ; ANRS Methaville study group ; the ANRS Methaville study group</creatorcontrib><description>Rationale/objectives
Sleep disturbance is frequent in opioid-dependent patients. To date, no data are available about the impact of methadone maintenance treatment on sleep disturbance. Using 1-year follow-up data from the Methaville trial, we investigated the impact of methadone initiation and other correlates on sleep disturbance in opioid-dependent patients.
Methods
Sleep disturbance severity was evaluated using two items from different scales (Center for Epidemiological Studies Depression Scale for depression and Opiate Treatment Index). We assessed the effect of methadone and other correlates on sleep disturbance severity during follow-up (months 0, 6, and 12) using a mixed multinomial logistic regression model.
Results
We included 173 patients who had 1-year follow-up data on sleep disturbance, corresponding to 445 visits. At enrolment, 60.5 % reported medium to severe sleep disturbance. This proportion remained stable during methadone treatment: 54.0 % at month 6 and 55.4 % at month 12. The final multivariate model indicated that younger patients (odds ratio (OR) [95 % CI] 0.95 [0.90–1.00]), patients with pain (OR [95 % CI] 2.45 [1.13–5.32]), patients with high or very high nicotine dependence (OR [95 % CI] 5.89 [2.41–14.39]), and patients at suicidal risk (2.50 [1.13–5.52]) had a higher risk of severe sleep disturbance. Because of collinearity between suicidal risk and attention deficit hyperactivity disorder (ADHD) symptoms, ADHD was not associated with sleep disturbance in the final model. Receiving methadone treatment had no significant effect on sleep disturbance.
Conclusions
Sleep disturbance is frequent among opioid-dependent patients. It can be regarded as an important signal of more complex psychiatric comorbidities such as suicidal risk and ADHD. However, sleep disturbance should not be considered an obstacle to methadone maintenance treatment (MMT) initiation or continuation.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/s00213-016-4202-4</identifier><identifier>PMID: 26753792</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Analgesics, Opioid - therapeutic use ; Biomedical and Life Sciences ; Biomedicine ; Comorbidity ; Drug abuse ; Female ; Health aspects ; Humans ; Longitudinal Studies ; Male ; Mental disorders ; Methadone ; Methadone - therapeutic use ; Narcotic Antagonists - therapeutic use ; Neurosciences ; Opiate Substitution Treatment ; Opioid-Related Disorders - complications ; Opioid-Related Disorders - physiopathology ; Opioid-Related Disorders - rehabilitation ; Original Investigation ; Pharmacology/Toxicology ; Prospective Studies ; Psychiatric Status Rating Scales ; Psychiatry ; Psychological aspects ; Sleep ; Sleep disorders ; Sleep Wake Disorders - complications ; Sleep Wake Disorders - physiopathology ; Studies</subject><ispartof>Psychopharmacology, 2016-04, Vol.233 (7), p.1203-1213</ispartof><rights>Springer-Verlag Berlin Heidelberg 2016</rights><rights>COPYRIGHT 2016 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c472t-29f74b7fa97c1d55d881c507aef3a34e63635e1287f282ccb0a9dafaca1f98713</citedby><cites>FETCH-LOGICAL-c472t-29f74b7fa97c1d55d881c507aef3a34e63635e1287f282ccb0a9dafaca1f98713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00213-016-4202-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00213-016-4202-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26753792$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nordmann, Sandra</creatorcontrib><creatorcontrib>Lions, Caroline</creatorcontrib><creatorcontrib>Vilotitch, Antoine</creatorcontrib><creatorcontrib>Michel, Laurent</creatorcontrib><creatorcontrib>Mora, Marion</creatorcontrib><creatorcontrib>Spire, Bruno</creatorcontrib><creatorcontrib>Maradan, Gwenaelle</creatorcontrib><creatorcontrib>Morel, Alain</creatorcontrib><creatorcontrib>Roux, Perrine</creatorcontrib><creatorcontrib>Carrieri, M. Patrizia</creatorcontrib><creatorcontrib>ANRS Methaville study group</creatorcontrib><creatorcontrib>the ANRS Methaville study group</creatorcontrib><title>A prospective, longitudinal study of sleep disturbance and comorbidity in opiate dependence (the ANRS Methaville study)</title><title>Psychopharmacology</title><addtitle>Psychopharmacology</addtitle><addtitle>Psychopharmacology (Berl)</addtitle><description>Rationale/objectives
Sleep disturbance is frequent in opioid-dependent patients. To date, no data are available about the impact of methadone maintenance treatment on sleep disturbance. Using 1-year follow-up data from the Methaville trial, we investigated the impact of methadone initiation and other correlates on sleep disturbance in opioid-dependent patients.
Methods
Sleep disturbance severity was evaluated using two items from different scales (Center for Epidemiological Studies Depression Scale for depression and Opiate Treatment Index). We assessed the effect of methadone and other correlates on sleep disturbance severity during follow-up (months 0, 6, and 12) using a mixed multinomial logistic regression model.
Results
We included 173 patients who had 1-year follow-up data on sleep disturbance, corresponding to 445 visits. At enrolment, 60.5 % reported medium to severe sleep disturbance. This proportion remained stable during methadone treatment: 54.0 % at month 6 and 55.4 % at month 12. The final multivariate model indicated that younger patients (odds ratio (OR) [95 % CI] 0.95 [0.90–1.00]), patients with pain (OR [95 % CI] 2.45 [1.13–5.32]), patients with high or very high nicotine dependence (OR [95 % CI] 5.89 [2.41–14.39]), and patients at suicidal risk (2.50 [1.13–5.52]) had a higher risk of severe sleep disturbance. Because of collinearity between suicidal risk and attention deficit hyperactivity disorder (ADHD) symptoms, ADHD was not associated with sleep disturbance in the final model. Receiving methadone treatment had no significant effect on sleep disturbance.
Conclusions
Sleep disturbance is frequent among opioid-dependent patients. It can be regarded as an important signal of more complex psychiatric comorbidities such as suicidal risk and ADHD. However, sleep disturbance should not be considered an obstacle to methadone maintenance treatment (MMT) initiation or continuation.</description><subject>Adult</subject><subject>Analgesics, Opioid - therapeutic use</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Comorbidity</subject><subject>Drug abuse</subject><subject>Female</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Mental disorders</subject><subject>Methadone</subject><subject>Methadone - therapeutic use</subject><subject>Narcotic Antagonists - therapeutic use</subject><subject>Neurosciences</subject><subject>Opiate Substitution Treatment</subject><subject>Opioid-Related Disorders - complications</subject><subject>Opioid-Related Disorders - physiopathology</subject><subject>Opioid-Related Disorders - rehabilitation</subject><subject>Original Investigation</subject><subject>Pharmacology/Toxicology</subject><subject>Prospective Studies</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychiatry</subject><subject>Psychological aspects</subject><subject>Sleep</subject><subject>Sleep disorders</subject><subject>Sleep Wake Disorders - complications</subject><subject>Sleep Wake Disorders - physiopathology</subject><subject>Studies</subject><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkstu1TAQhi0EoqeFB2CDLLEpEim-xsnyqIKCVEDisrYce3zqKscOcVJ03h6HlKtAwl7YGn__aGb8I_SIkjNKiHqeCWGUV4TWlWCEVeIO2lDBWcWIYnfRhhDOK05lc4SOc74mZYlG3EdHrFaSq5Zt0JctHsaUB7BTuIFnuE9xF6bZhWh6nMvlgJPHuQcYsAslMHYmWsAmOmzTPo1dcGE64BBxGoKZADsYIDpYoNPpCvD27fsP-A1MV-Ym9D2sSZ8-QPe86TM8vD1P0KeXLz6ev6ou3128Pt9eVlYoNlWs9Up0yptWWeqkdE1DrSTKgOeGC6h5zSVQ1ijPGmZtR0zrjDfWUN82ivITdLrmLV1-niFPeh-yhb43EdKcNVUNkcuI5H-gy9AK2Bb0yR_odZrHMrJvVKm8lar5Se1MDzpEn6bR2CWp3gqhSC0k54U6-wtVtoN9sCmCDyX-m4CuAls-Lo_g9TCGvRkPmhK9-EKvvtDFF3rxhRZF8_i24Lnbg_uh-G6EArAVyOUp7mD8paN_Zv0KyvPBBA</recordid><startdate>20160401</startdate><enddate>20160401</enddate><creator>Nordmann, Sandra</creator><creator>Lions, Caroline</creator><creator>Vilotitch, Antoine</creator><creator>Michel, Laurent</creator><creator>Mora, Marion</creator><creator>Spire, Bruno</creator><creator>Maradan, Gwenaelle</creator><creator>Morel, Alain</creator><creator>Roux, Perrine</creator><creator>Carrieri, M. Patrizia</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QR</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20160401</creationdate><title>A prospective, longitudinal study of sleep disturbance and comorbidity in opiate dependence (the ANRS Methaville study)</title><author>Nordmann, Sandra ; Lions, Caroline ; Vilotitch, Antoine ; Michel, Laurent ; Mora, Marion ; Spire, Bruno ; Maradan, Gwenaelle ; Morel, Alain ; Roux, Perrine ; Carrieri, M. Patrizia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c472t-29f74b7fa97c1d55d881c507aef3a34e63635e1287f282ccb0a9dafaca1f98713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Analgesics, Opioid - therapeutic use</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Comorbidity</topic><topic>Drug abuse</topic><topic>Female</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Mental disorders</topic><topic>Methadone</topic><topic>Methadone - therapeutic use</topic><topic>Narcotic Antagonists - therapeutic use</topic><topic>Neurosciences</topic><topic>Opiate Substitution Treatment</topic><topic>Opioid-Related Disorders - complications</topic><topic>Opioid-Related Disorders - physiopathology</topic><topic>Opioid-Related Disorders - rehabilitation</topic><topic>Original Investigation</topic><topic>Pharmacology/Toxicology</topic><topic>Prospective Studies</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychiatry</topic><topic>Psychological aspects</topic><topic>Sleep</topic><topic>Sleep disorders</topic><topic>Sleep Wake Disorders - complications</topic><topic>Sleep Wake Disorders - physiopathology</topic><topic>Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nordmann, Sandra</creatorcontrib><creatorcontrib>Lions, Caroline</creatorcontrib><creatorcontrib>Vilotitch, Antoine</creatorcontrib><creatorcontrib>Michel, Laurent</creatorcontrib><creatorcontrib>Mora, Marion</creatorcontrib><creatorcontrib>Spire, Bruno</creatorcontrib><creatorcontrib>Maradan, Gwenaelle</creatorcontrib><creatorcontrib>Morel, Alain</creatorcontrib><creatorcontrib>Roux, Perrine</creatorcontrib><creatorcontrib>Carrieri, M. Patrizia</creatorcontrib><creatorcontrib>ANRS Methaville study group</creatorcontrib><creatorcontrib>the ANRS Methaville study group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nordmann, Sandra</au><au>Lions, Caroline</au><au>Vilotitch, Antoine</au><au>Michel, Laurent</au><au>Mora, Marion</au><au>Spire, Bruno</au><au>Maradan, Gwenaelle</au><au>Morel, Alain</au><au>Roux, Perrine</au><au>Carrieri, M. Patrizia</au><aucorp>ANRS Methaville study group</aucorp><aucorp>the ANRS Methaville study group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A prospective, longitudinal study of sleep disturbance and comorbidity in opiate dependence (the ANRS Methaville study)</atitle><jtitle>Psychopharmacology</jtitle><stitle>Psychopharmacology</stitle><addtitle>Psychopharmacology (Berl)</addtitle><date>2016-04-01</date><risdate>2016</risdate><volume>233</volume><issue>7</issue><spage>1203</spage><epage>1213</epage><pages>1203-1213</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><abstract>Rationale/objectives
Sleep disturbance is frequent in opioid-dependent patients. To date, no data are available about the impact of methadone maintenance treatment on sleep disturbance. Using 1-year follow-up data from the Methaville trial, we investigated the impact of methadone initiation and other correlates on sleep disturbance in opioid-dependent patients.
Methods
Sleep disturbance severity was evaluated using two items from different scales (Center for Epidemiological Studies Depression Scale for depression and Opiate Treatment Index). We assessed the effect of methadone and other correlates on sleep disturbance severity during follow-up (months 0, 6, and 12) using a mixed multinomial logistic regression model.
Results
We included 173 patients who had 1-year follow-up data on sleep disturbance, corresponding to 445 visits. At enrolment, 60.5 % reported medium to severe sleep disturbance. This proportion remained stable during methadone treatment: 54.0 % at month 6 and 55.4 % at month 12. The final multivariate model indicated that younger patients (odds ratio (OR) [95 % CI] 0.95 [0.90–1.00]), patients with pain (OR [95 % CI] 2.45 [1.13–5.32]), patients with high or very high nicotine dependence (OR [95 % CI] 5.89 [2.41–14.39]), and patients at suicidal risk (2.50 [1.13–5.52]) had a higher risk of severe sleep disturbance. Because of collinearity between suicidal risk and attention deficit hyperactivity disorder (ADHD) symptoms, ADHD was not associated with sleep disturbance in the final model. Receiving methadone treatment had no significant effect on sleep disturbance.
Conclusions
Sleep disturbance is frequent among opioid-dependent patients. It can be regarded as an important signal of more complex psychiatric comorbidities such as suicidal risk and ADHD. However, sleep disturbance should not be considered an obstacle to methadone maintenance treatment (MMT) initiation or continuation.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>26753792</pmid><doi>10.1007/s00213-016-4202-4</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0033-3158 |
| ispartof | Psychopharmacology, 2016-04, Vol.233 (7), p.1203-1213 |
| issn | 0033-3158 1432-2072 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1780531585 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Analgesics, Opioid - therapeutic use Biomedical and Life Sciences Biomedicine Comorbidity Drug abuse Female Health aspects Humans Longitudinal Studies Male Mental disorders Methadone Methadone - therapeutic use Narcotic Antagonists - therapeutic use Neurosciences Opiate Substitution Treatment Opioid-Related Disorders - complications Opioid-Related Disorders - physiopathology Opioid-Related Disorders - rehabilitation Original Investigation Pharmacology/Toxicology Prospective Studies Psychiatric Status Rating Scales Psychiatry Psychological aspects Sleep Sleep disorders Sleep Wake Disorders - complications Sleep Wake Disorders - physiopathology Studies |
| title | A prospective, longitudinal study of sleep disturbance and comorbidity in opiate dependence (the ANRS Methaville study) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T08%3A59%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20prospective,%20longitudinal%20study%20of%20sleep%20disturbance%20and%20comorbidity%20in%20opiate%20dependence%20(the%20ANRS%20Methaville%20study)&rft.jtitle=Psychopharmacology&rft.au=Nordmann,%20Sandra&rft.aucorp=ANRS%20Methaville%20study%20group&rft.date=2016-04-01&rft.volume=233&rft.issue=7&rft.spage=1203&rft.epage=1213&rft.pages=1203-1213&rft.issn=0033-3158&rft.eissn=1432-2072&rft_id=info:doi/10.1007/s00213-016-4202-4&rft_dat=%3Cgale_proqu%3EA447064533%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1774729578&rft_id=info:pmid/26753792&rft_galeid=A447064533&rfr_iscdi=true |